- Home
- CPRX vs WLYB Comparison
CPRX vs WLYB Comparison
Compare CPRX & WLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRX
- WLYB
- Stock Information
- Founded
- CPRX 2002
- WLYB 1807
- Country
- CPRX United States
- WLYB United States
- Employees
- CPRX N/A
- WLYB N/A
- Industry
- CPRX Biotechnology: Pharmaceutical Preparations
- WLYB Books
- Sector
- CPRX Health Care
- WLYB Consumer Discretionary
- Exchange
- CPRX Nasdaq
- WLYB Nasdaq
- Market Cap
- CPRX 2.5B
- WLYB 2.7B
- IPO Year
- CPRX 2006
- WLYB N/A
- Fundamental
- Price
- CPRX $22.34
- WLYB $45.38
- Analyst Decision
- CPRX Strong Buy
- WLYB
- Analyst Count
- CPRX 7
- WLYB 0
- Target Price
- CPRX $31.14
- WLYB N/A
- AVG Volume (30 Days)
- CPRX 820.3K
- WLYB 151.0
- Earning Date
- CPRX 11-06-2024
- WLYB 12-05-2024
- Dividend Yield
- CPRX N/A
- WLYB 3.08%
- EPS Growth
- CPRX 114.68
- WLYB N/A
- EPS
- CPRX 1.18
- WLYB N/A
- Revenue
- CPRX $460,482,000.00
- WLYB $1,759,570,000.00
- Revenue This Year
- CPRX $23.98
- WLYB N/A
- Revenue Next Year
- CPRX $18.27
- WLYB $1.12
- P/E Ratio
- CPRX $18.72
- WLYB N/A
- Revenue Growth
- CPRX 32.17
- WLYB N/A
- 52 Week Low
- CPRX $13.12
- WLYB $30.64
- 52 Week High
- CPRX $24.27
- WLYB $52.90
- Technical
- Relative Strength Index (RSI)
- CPRX 54.94
- WLYB 24.20
- Support Level
- CPRX $20.93
- WLYB $49.30
- Resistance Level
- CPRX $22.49
- WLYB $52.29
- Average True Range (ATR)
- CPRX 0.60
- WLYB 0.13
- MACD
- CPRX 0.00
- WLYB -0.46
- Stochastic Oscillator
- CPRX 77.06
- WLYB 1.15
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
About WLYB John Wiley & Sons Inc.
John Wiley & Sons Inc is a provider of academic journals, books, pre- and post-hire assessments and training, test preparation materials, and online education program management solutions. The company's reportable segments are; Research, Learning, Held for Sale or Sold. The majority of the company's revenue is generated from the Research segment which provides peer-reviewed scientific, technical, and medical (STM) publishing, content platforms, and related services to academic, corporate, and government customers, academic societies, and individual researchers. Geographically, it derives maximum revenue from the United States and the rest from the United Kingdom, China, Japan, Canada, and other countries.